Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. Virtus LifeSci Biotech Products ETF (BBP) is part of the Tomorrow's Treatments segment. ARKG's top 3 sector exposures are Health Care and Information Technology. In contrast, BBP's top sector exposures are Health Care ARKG is less expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.79% for BBP. ARKG is down -9.75% year-to-date (YTD) with -$22M in YTD flows. BBP performs better with 2.1% YTD performance, and +$4M in YTD flows. Run a side-by-side ETF comparison of ARKG and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG BBP | -7.14%+0.58% | -11.85%+3.36% | -9.75%+2.10% | +19.69%+35.25% | -7.59%+67.03% | -71.74%+48.61% |
| Flows | ARKG BBP | -$116M+$4M | -$77M+$16M | -$22M+$4M | -$189M+$19M | -$639M+$19M | -$2.98B+$9M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG BBP | +40.48%+25.64% | +44.71%+25.72% | +42.32%+23.44% | +45.24%+26.15% |
| Max drawdown | ARKG BBP | -23.49%-7.42% | -23.94%-17.97% | -51.98%-25.54% | -80.33%-38.24% |
| Max drawdown duration | ARKG BBP | 50d32d | 77d106d | 968d292d | 1824d915d |
ARKG | BBP | |
Last sale 3/16/2026 at 1:30 PM | $26.55 | $82.46 |
| Previous close 03/13/2026 | $26.36 | $81.25 |
| Consolidated volume 03/13/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
ARKG | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
ARKG | BBP | |
|---|---|---|
| Last price | $26.55 | $82.46 |
| 1D performance | +0.72% | +1.49% |
| AuM | $1.04 B | $48.86 M |
| E/R | 0.75% | 0.79% |
ARKG | BBP | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | VIRTUS Investment Partners |
| Benchmark | - | LifeSci Biotechnology Products Index |
| N° of holdings | 30 | 58 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | December 16, 2014 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
